These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30971460)

  • 1. Understanding and Addressing CLSI Breakpoint Revisions: a Primer for Clinical Laboratories.
    Humphries RM; Abbott AN; Hindler JA
    J Clin Microbiol; 2019 Jun; 57(6):. PubMed ID: 30971460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Don't Get Wound Up: Revised Fluoroquinolone Breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa.
    Van TT; Minejima E; Chiu CA; Butler-Wu SM
    J Clin Microbiol; 2019 Jul; 57(7):. PubMed ID: 31043468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The New, New Daptomycin Breakpoint for
    Humphries RM
    J Clin Microbiol; 2019 Jul; 57(7):. PubMed ID: 31092593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Clinical Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing guidelines for the interpretation of antibiotic susceptibility at a University teaching hospital in Nairobi, Kenya: a cross-sectional study.
    Kassim A; Omuse G; Premji Z; Revathi G
    Ann Clin Microbiol Antimicrob; 2016 Apr; 15():21. PubMed ID: 27068515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surveillance of Fluoroquinolone Resistance in Wisconsin: Geographic Variation and Impact of Revised CLSI Breakpoints.
    Lazzerini G; Lavey SC; Fox BC; Munson E
    Clin Med Res; 2022 Jun; 20(2):81-88. PubMed ID: 35086853
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of Ciprofloxacin and Levofloxacin Disk Diffusion and Etest Using the 2019
    Humphries RM; Hindler JA; Shaffer K; Campeau SA
    J Clin Microbiol; 2019 Mar; 57(3):. PubMed ID: 30567744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Delays between Clinical and Laboratory Standards Institute and Food and Drug Administration Revisions of Interpretive Criteria for Carbapenem-Resistant Enterobacteriaceae.
    Bartsch SM; Huang SS; Wong KF; Slayton RB; McKinnell JA; Sahm DF; Kazmierczak K; Mueller LE; Jernigan JA; Lee BY
    J Clin Microbiol; 2016 Nov; 54(11):2757-2762. PubMed ID: 27582516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of Changes to the Clinical and Laboratory Standards Institute
    Humphries R; Bobenchik AM; Hindler JA; Schuetz AN
    J Clin Microbiol; 2021 Nov; 59(12):e0021321. PubMed ID: 34550809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Setting Antimicrobial Susceptibility Testing Breakpoints: A Primer for Pediatric Infectious Diseases Specialists on the Clinical and Laboratory Standards Institute Approach.
    Pierce VM; Mathers AJ
    J Pediatric Infect Dis Soc; 2022 Feb; 11(2):73-80. PubMed ID: 34888640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of Vitek 2 for antimicrobial susceptibility testing of Enterobacteriaceae with Vitek 2 (2009 FDA) and 2014 CLSI breakpoints.
    Bobenchik AM; Deak E; Hindler JA; Charlton CL; Humphries RM
    J Clin Microbiol; 2015 Mar; 53(3):816-23. PubMed ID: 25540403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Revised Ceftaroline Disk Diffusion Breakpoints When Testing a Challenge Collection of Methicillin-Resistant Staphylococcus aureus Isolates.
    Sader HS; Rhomberg PR; Doyle TB; Flamm RK; Mendes RE
    J Clin Microbiol; 2018 Dec; 56(12):. PubMed ID: 30257898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How New Regulation of Laboratory-Developed Antimicrobial Susceptibility Tests Will Affect Infectious Diseases Clinical Practice.
    Wolfe KH; Pierce VM; Humphries RM
    Clin Infect Dis; 2024 May; 78(5):1140-1147. PubMed ID: 38573057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twenty-first Century Cures Act and Antimicrobial Susceptibility Testing: Clinical Implications in the Era of Multidrug Resistance.
    Humphries RM; Hindler J; Jane Ferraro M; Mathers A
    Clin Infect Dis; 2018 Sep; 67(7):1132-1138. PubMed ID: 29796616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the Phoenix™ automated system and EUCAST breakpoints for antimicrobial susceptibility testing against isolates expressing clinically relevant resistance mechanisms.
    Giani T; Morosini MI; D'Andrea MM; García-Castillo M; Rossolini GM; Cantón R
    Clin Microbiol Infect; 2012 Nov; 18(11):E452-8. PubMed ID: 22909279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment.
    DeRyke CA; Kuti JL; Nicolau DP
    Diagn Microbiol Infect Dis; 2007 Jul; 58(3):337-44. PubMed ID: 17350206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Oxacillin and Cefoxitin Disk and MIC Breakpoints for Prediction of Methicillin Resistance in Human and Veterinary Isolates of Staphylococcus intermedius Group.
    Wu MT; Burnham CA; Westblade LF; Dien Bard J; Lawhon SD; Wallace MA; Stanley T; Burd E; Hindler J; Humphries RM
    J Clin Microbiol; 2016 Mar; 54(3):535-42. PubMed ID: 26607988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of CLSI Breakpoint Changes on Microbiology Laboratories and Antimicrobial Stewardship Programs.
    Heil EL; Johnson JK
    J Clin Microbiol; 2016 Apr; 54(4):840-4. PubMed ID: 26791363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical breakpoint changes and their impact on surveillance of antimicrobial resistance in Escherichia coli causing bacteraemia.
    van der Bij AK; van Dijk K; Muilwijk J; Thijsen SF; Notermans DW; de Greeff S; van de Sande-Bruinsma N;
    Clin Microbiol Infect; 2012 Nov; 18(11):E466-72. PubMed ID: 22925456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa.
    Sader HS; Rhomberg PR; Huband MD; Critchley IA; Stone GG; Flamm RK; Jones RN
    J Clin Microbiol; 2018 Jun; 56(6):. PubMed ID: 29563198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of Vitek 2 for Antimicrobial Susceptibility Testing of Acinetobacter baumannii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia with Vitek 2 (2009 FDA) and CLSI M100S 26th Edition Breakpoints.
    Bobenchik AM; Deak E; Hindler JA; Charlton CL; Humphries RM
    J Clin Microbiol; 2017 Feb; 55(2):450-456. PubMed ID: 27881616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.